MX2023012595A - Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv. - Google Patents
Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv.Info
- Publication number
- MX2023012595A MX2023012595A MX2023012595A MX2023012595A MX2023012595A MX 2023012595 A MX2023012595 A MX 2023012595A MX 2023012595 A MX2023012595 A MX 2023012595A MX 2023012595 A MX2023012595 A MX 2023012595A MX 2023012595 A MX2023012595 A MX 2023012595A
- Authority
- MX
- Mexico
- Prior art keywords
- ndv
- apmv
- protein
- nucleotide sequence
- sequence encoding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179994P | 2021-04-26 | 2021-04-26 | |
| US202263302434P | 2022-01-24 | 2022-01-24 | |
| PCT/US2022/026185 WO2022232052A1 (en) | 2021-04-26 | 2022-04-25 | Chimeric newcastle disease virus expressing apmv hn and f proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012595A true MX2023012595A (es) | 2023-11-28 |
Family
ID=83848644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012595A MX2023012595A (es) | 2021-04-26 | 2022-04-25 | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240199705A1 (enExample) |
| EP (1) | EP4329886A4 (enExample) |
| JP (1) | JP2024514975A (enExample) |
| KR (1) | KR20240001198A (enExample) |
| AU (1) | AU2022267223A1 (enExample) |
| CA (1) | CA3215468A1 (enExample) |
| CO (1) | CO2023015564A2 (enExample) |
| MX (1) | MX2023012595A (enExample) |
| WO (1) | WO2022232052A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| CN117778471A (zh) * | 2023-12-25 | 2024-03-29 | 华南农业大学 | 克服新城疫母源抗体影响的重组新城疫病毒载体及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3041490T3 (pl) * | 2013-09-03 | 2019-05-31 | Medimmune Ltd | Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji |
| CA3106170A1 (en) * | 2018-07-13 | 2020-01-16 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| EP3837277A4 (en) * | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
-
2022
- 2022-04-25 KR KR1020237040448A patent/KR20240001198A/ko active Pending
- 2022-04-25 AU AU2022267223A patent/AU2022267223A1/en active Pending
- 2022-04-25 MX MX2023012595A patent/MX2023012595A/es unknown
- 2022-04-25 US US18/556,458 patent/US20240199705A1/en active Pending
- 2022-04-25 JP JP2023565511A patent/JP2024514975A/ja active Pending
- 2022-04-25 CA CA3215468A patent/CA3215468A1/en active Pending
- 2022-04-25 WO PCT/US2022/026185 patent/WO2022232052A1/en not_active Ceased
- 2022-04-25 EP EP22796499.6A patent/EP4329886A4/en active Pending
-
2023
- 2023-11-17 CO CONC2023/0015564A patent/CO2023015564A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329886A1 (en) | 2024-03-06 |
| US20240199705A1 (en) | 2024-06-20 |
| AU2022267223A1 (en) | 2023-11-02 |
| CA3215468A1 (en) | 2022-11-03 |
| AU2022267223A9 (en) | 2023-11-16 |
| JP2024514975A (ja) | 2024-04-03 |
| KR20240001198A (ko) | 2024-01-03 |
| WO2022232052A1 (en) | 2022-11-03 |
| CO2023015564A2 (es) | 2023-11-30 |
| EP4329886A4 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv | |
| MX2020011257A (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| AR089039A1 (es) | Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos | |
| MX2019011599A (es) | Moleculas quimericas y usos de las mismas. | |
| MX2020012469A (es) | Variante de antigeno de virus de varicela zoster y uso de la misma. | |
| EA200801756A1 (ru) | Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса | |
| MX2024004297A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| BR112022022644A2 (pt) | Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas | |
| NZ595736A (en) | Chimeric viruses presenting non-native surface proteins and uses thereof | |
| BR112022022604A2 (pt) | Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos | |
| HRP20220980T1 (hr) | Cjepiva protiv virusa influence i njihova uporaba | |
| BR112015032556A2 (pt) | Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo | |
| Wei et al. | Development and characterization of a recombinant infectious bronchitis virus expressing the ectodomain region of S1 gene of H120 strain | |
| AR056133A1 (es) | Virus de influenza canina y composiciones relacionadas y metodos de uso | |
| MX2018015756A (es) | Construcciones de virus de la enfermedad de marek recombinantes no patogenicas codificadoras de antigenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad bursal infecciosa. | |
| ES2570758T3 (es) | Materiales y métodos para el control de enfermedades respiratorias en cánidos | |
| AR129904A2 (es) | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagación incrementada en las células | |
| PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| MX2024008983A (es) | Polipeptidos quimericos | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| AR124522A1 (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2 | |
| Li et al. | Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail | |
| UY39916A (es) | Partículas de aav que comprenden una proteína de la cápside hepatotrópica y alfa-galactosidasa y su uso para tratar la enfermedad de fabry | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis |